

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:


1. (Withdrawn-currently amended): A method for treatment and/or prevention of a disease due to constriction or vasodilation of blood vessels, which comprises administering to a mammal an effective dose of ~~an EDG-5 modulator~~the compound according to claim 10.

2. (Withdrawn-previously presented): The method according to claim 1, wherein the disease due to constriction or vasodilation of blood vessels is selected from cerebrovascular spasmodic disorder, cardiovascular spasmodic disorder, hypertension, renal disease, cardiac infarction, cardiac angina, arrhythmia, facilitation of the portal blood pressure, varicosity, chronic headache, haemorrhoid and congestive disorder.

3. (Withdrawn-currently amended): The method according to claim 2, wherein the blood vessel is a cerebral artery, a renal artery, a coronary artery, a pulmonary artery, a aorta ~~and/or~~ a vein.

4-9. (Canceled).


10. (Currently amended): A compound represented by formula (I):



wherein: all the symbols have the same meanings as those of claim 6, or

_____ a pharmaceutically acceptable salt thereof

A represents



wherein R¹ represents a substituent,

R² represents hydroxy or C1-6 alkoxyl,

R³ represents a substituent, and

r represents 0 or an integer of 1-4,

X represents a single bond,

Y represents -CO- or -CS-,

Z represents a nitrogen atom optionally substituted with C1-6 alkoxyl,

B represents a cyclic group optionally with a substituent(s),

or a pharmaceutically acceptable salt thereof.

11-19. (Canceled).

20. (Currently amended): The compound according to claim 17, wherein R² is hydroxy.

21. (Canceled).

22. (Original): The compound according to claim 20, wherein R¹ is a chain substituent.

23. (Canceled).

24. (Original): The compound according to claim 22, wherein the chain substituent is alkyl.

25. (Original): The compound according to claim 22, wherein the chain substituent is substituted alkyl.


26. (Canceled).

27. (Original): The compound according to claim 24, wherein the cyclic group optionally with a substituent(s) represented by B is an aromatic ring.

28. (Canceled).

29. (Original): The compound according to claim 27, wherein the cyclic group is substituted with 1 or at least 2 substituent(s).

30. (Original): The compound according to claim 29, wherein the cyclic group with at least 2 substituents is



wherein B¹ represents a carbon ring of an aromatic ring,

R¹¹ and R¹² each represents a substituent,

m represents an integer of 1-4, and

the other symbols have the same meanings as those mentioned above.


32-43. (Canceled).

44. (Currently amended): The compound according to claim ~~44~~10, wherein the cyclic group optionally with a substituent(s) represented by B is an aromatic ring.

45. (Canceled).

46. (Original): The compound according to claim 44, wherein the cyclic group is substituted with 1 or at least 2 substituent(s).

47. (Original): The compound according to claim 46, wherein the cyclic group with at least 2 substituents is



wherein B¹ represents a carbon ring of an aromatic ring,

R¹¹ and R¹² each represents a substituent

m represents an integer of 1-4, and

the other symbols have the same meanings as those mentioned above.


48. (Canceled).

49. (Original): The compound according to claim 25, wherein the cyclic group optionally with a substituent(s) represented by B is an aromatic ring.

50. (Canceled).

51. (Currently amended): The compound according to claim 49, wherein the cyclic group is substituted with 1 or at least 2 substituents.

52. (Currently amended): The compound according to claim 51, wherein the cyclic group with at least 2 substituents is



wherein B¹ represents a carbon ring of an aromatic ring,


R¹¹ and R¹² each represents a substituent,

M_m represents an integer of 1-4, and

the other symbols have the same meanings as those mentioned above.

53-60. (Canceled).

61. (Withdrawn-currently amended): A method for treatment and/or prevention of a disease due to constriction of blood vessels in a mammal, which comprises administering to a mammal an effective dose of ~~a the compound~~ according to claim 10 or represented by formula (I):



_____ wherein all the symbols have the same meanings as those of claim 6, or
_____ a pharmaceutically salt acceptable thereof.

62. (Withdrawn-currently amended): A method for inhibition of EDG-5 in a mammal, which comprises administering to a mammal an effective dose of the compound according to claim 10 or a pharmaceutically acceptable salt thereof, wherein the cyclic group optionally with a substituent(s) represented by A, or the cyclic group optionally with a substituent(s) represented by B is a C3-15 carbon ring, or an optionally saturated or unsaturated 3-15-membered monocyclic, bicyclic, or tricyclic aromatic heterocyclic ring, except pyrazolo[3,4-b]pyridine, containing 1-5 hetero atoms selected from an oxygen atom(s), a nitrogen atom(s), and/or a sulfur atom(s).

63-70. (Canceled).